OPIANT PHARMACEUTICALS, INC.: 10-K filed 2019-03-21

Name: OPIANT PHARMACEUTICALS, INC.: 10-K filed 2019-03-21
Creator: OPIANT PHARMACEUTICALS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What OPIANT PHARMACEUTICALS, INC. reported in its annual report filed 2019-03-21 (fiscal FY 2018): 31 published measures, 104 facts as tagged in accession 0001385508-19-000028.

This filing

Form: 10-K (annual report)
Filed: 2019-03-21
Fiscal period: fiscal FY 2018
Accession: 0001385508-19-000028 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit
At 2018-12-31	29,386,324	USD
At 2017-12-31	20,773,250	USD
At 2017-07-31	10,807,885	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit
At 2018-12-31	12,527,058	USD
At 2017-12-31	7,772,998	USD
At 2017-07-31	6,473,476	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2018-12-31	16,859,266	USD
At 2017-12-31	13,000,252	USD
At 2017-07-31	4,334,409	USD
At 2016-07-31	-4,704,956	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2018-12-31	24,613,638	USD
At 2017-12-31	8,115,903	USD
At 2017-07-31	6,872,555	USD
At 2016-07-31	1,481,393	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-21,195,316	USD	365
2017-08-01 to 2017-12-31	1,379,379	USD	153
2017-01-01 to 2017-12-31	-2,606,000	USD	365
2016-08-01 to 2017-07-31	6,580,613	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-522,972	USD	365
2017-08-01 to 2017-12-31	-3,840,486	USD	153
2016-08-01 to 2017-07-31	5,556,162	USD	365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	13,982,177	USD	365
2017-08-01 to 2017-12-31	11,762,317	USD	153
2017-01-01 to 2017-12-31	15,552,000	USD	365
2016-08-01 to 2017-07-31	18,445,996	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	17,020,707	USD	365
2017-08-01 to 2017-12-31	5,083,834	USD	153
2016-08-01 to 2017-07-31	-165,000	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit
At 2018-12-31	-74,420,666	USD
At 2017-12-31	-53,225,350	USD
At 2017-07-31	-54,604,729	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	2,985,335	shares	365
2017-08-01 to 2017-12-31	2,077,663	shares	153
2016-08-01 to 2017-07-31	2,014,540	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	2,985,335	shares	365
2017-08-01 to 2017-12-31	4,393,138	shares	153
2016-08-01 to 2017-07-31	2,235,851	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-7.1	USD/shares	365
2017-08-01 to 2017-12-31	0.66	USD/shares	153
2016-08-01 to 2017-07-31	3.27	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-7.1	USD/shares	365
2017-08-01 to 2017-12-31	0.31	USD/shares	153
2016-08-01 to 2017-07-31	2.94	USD/shares	365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	51,283	USD	365
2017-08-01 to 2017-12-31	169,163	USD	153
2017-01-01 to 2017-12-31	797,000	USD	365
2016-08-01 to 2017-07-31	550,474	USD	365
2015-08-01 to 2016-07-31	550,474	USD	366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit
At 2018-12-31	0	USD
At 2017-12-31	1,183	USD
At 2017-07-31	2,753	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	5,700,000	USD	365
2017-08-01 to 2017-12-31	1,800,000	USD	153
2016-08-01 to 2017-07-31	1,700,000	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-21,190,440	USD	365
2017-08-01 to 2017-12-31	1,542,031	USD	153
2017-01-01 to 2017-12-31	-1,877,000	USD	365
2016-08-01 to 2017-07-31	7,092,765	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit
At 2018-12-31	29,370,578	USD
At 2017-12-31	20,754,949	USD
At 2017-07-31	10,787,442	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit
At 2018-12-31	9,827,058	USD
At 2017-12-31	5,657,193	USD
At 2017-07-31	4,166,949	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit
At 2018-12-31	4,489,317	USD
At 2017-12-31	11,696,676	USD
At 2017-07-31	3,750,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	35,172,617	USD	365
2017-08-01 to 2017-12-31	10,220,286	USD	153
2017-01-01 to 2017-12-31	17,429,000	USD	365
2016-08-01 to 2017-07-31	11,353,231	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	8,478,817	USD	365
2017-08-01 to 2017-12-31	2,486,514	USD	153
2017-01-01 to 2017-12-31	4,857,000	USD	365
2016-08-01 to 2017-07-31	3,171,599	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit
At 2018-12-31	3,845,361	shares
At 2017-12-31	2,535,766	shares
At 2017-07-31	2,026,608	shares

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit
At 2018-12-31	15,746	USD
At 2017-12-31	17,118	USD
At 2017-07-31	17,690	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit
At 2018-12-31	267,623	USD
At 2017-12-31	733,328	USD
At 2017-07-31	164,887	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	11,263,804	USD	365
2017-08-01 to 2017-12-31	5,887,135	USD	153
2017-01-01 to 2017-12-31	10,313,000	USD	365
2016-08-01 to 2017-07-31	6,530,533	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	46,407	USD	365
2017-08-01 to 2017-12-31	6,511	USD	153
2017-01-01 to 2017-12-31	68,000	USD	365
2016-08-01 to 2017-07-31	38,322	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	0	USD	365
2017-08-01 to 2017-12-31	0	USD	153
2016-08-01 to 2017-07-31	4,828	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	17,153,126	USD	365
2017-08-01 to 2017-12-31	0	USD	153
2016-08-01 to 2017-07-31	0	USD	365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-7,207,359	USD	365
2017-08-01 to 2017-12-31	7,946,676	USD	153
2016-08-01 to 2017-07-31	3,437,502	USD	365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	-1,924,032	USD	365
2017-08-01 to 2017-12-31	1,145,021	USD	153
2016-08-01 to 2017-07-31	2,071,387	USD	365

Inspect the source

Entity: OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
Captured: 2026-09-22 19:47 UTC
SEC response SHA-256: 2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))